COMBINATION USE OF INHIBITOR TARGETING PD-1/PD-L1 AND COX-2 INHIBITOR
The present invention provides a novel therapeutic strategy using an inhibitor targeting PD-1/PD-L1. A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1. A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor.
1 . A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.
2 . The pharmaceutical composition of claim 1 , wherein the inhibitor targeting PD-1/PD-L1 is an antibody.
3 . The pharmaceutical composition of claim 1 , wherein the antibody is at least one antibody selected from the group consisting of anti-PD-1 antibody and anti-PD-L1 antibody.
4 . The pharmaceutical composition of claim 1 , wherein the COX-2 inhibitor is at least one compound selected from the group consisting of meloxicam, piroxicam, celecoxib, firocoxib, robenacoxib, carprofen and etodolac.
5 . The pharmaceutical composition of claim 1 for use in prevention and/or treatment of cancer and/or infection.
6 . The pharmaceutical composition of claim 1 , wherein the inhibitor targeting PD-1/PD-L1 and the COX-2 inhibitor are administered separately.
7 . The pharmaceutical composition of claim 1 , which is a combination drug comprising the inhibitor targeting PD-1/PD-L1 and the COX-2 inhibitor.
8 . A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor.
9 . A method of preventing and/or treating cancer and/or infection, comprising administering to a human or animal subject a pharmaceutically effective amount of a COX-2 inhibitor before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.
10 . Use of a COX-2 inhibitor for preventing and/or treating cancer and/or infection, wherein the COX-2 inhibitor is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.
11 . Use of a COX-2 inhibitor for use in a method of preventing and/or treating cancer and/or infection, wherein the COX-2 inhibitor is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.